← Search & browse all drugs

mebutizide and potassium-sparing agents

C03EA05

Forms & Strengths

Combination tablet: Mebutizide 2.5 mg / Potassium-sparing diuretic (e.g., Triamterene 50 mg)
Combination tablet: Mebutizide 5 mg / Potassium-sparing diuretic (e.g., Amiloride 5 mg)

Adult Dosing

Hypertension: 1 tablet daily, adjusted according to blood pressure response
Edema: 1 to 2 tablets daily in divided doses, depending on severity and clinical response

Pediatric Dosing

Safety and efficacy in pediatric patients not established; use is generally not recommended

Indications

Management of essential hypertension
Treatment of edema associated with congestive heart failure, hepatic cirrhosis, or nephrotic syndrome while minimizing potassium loss

Mechanism of Action

Mebutizide: Thiazide diuretic inhibiting sodium and chloride reabsorption in the distal convoluted tubule
Potassium-sparing agent: Acts on the distal renal tubules to inhibit sodium reabsorption and potassium excretion, mitigating thiazide-induced hypokalemia

Contraindications

Anuria or severe renal impairment (CrCl < 30 mL/min)
Hyperkalemia or conditions predisposing to hyperkalemia
Addison's disease
Hypersensitivity to thiazides, sulfonamide-derived drugs, or the potassium-sparing component

Adverse Reactions

Hyperkalemia
Hypotension and dizziness
Electrolyte imbalances (hyponatremia, hypomagnesemia)
Hyperuricemia and gout exacerbation
Hyperglycemia and dyslipidemia
Gastrointestinal disturbances (nausea, diarrhea)

Drug Interactions

ACE inhibitors, ARBs, and direct renin inhibitors: Increased risk of severe hyperkalemia
NSAIDs: May reduce the antihypertensive and diuretic efficacy and increase nephrotoxicity risk
Lithium: Decreased renal clearance leading to potential lithium toxicity
Other potassium supplements or potassium-rich salt substitutes: High risk of dangerous hyperkalemia

Curated Content: Needs Vetting Before Put to Clinical Use